Search results | schering


Sorry, your search returned no results.


Merial joins Intervet/Schering-Plough joint venture

A new global player in the animal health sector has been created as a result of Sanofi-Aventis exercising its option from a deal announced back in September 2009.

Merck & Schering Plough – Mega-merger that is greater than sum of its parts

Source: Datamonitor 

Merck & Co

Merck & Co is a top pharmaceutical company based in Whitehouse Station, NJ, USA

Merck could get $10 billion for its consumer health products

Merck & Co.’s effort to sell its portfolio of well-known consumer brands including Coppertone sun screen and Claritin allergy pills is kicking into high gear, with consumer and health care giants expected to put in bids that could top $10 billion, according to people familiar with the matter.

McKesson’s company acquisition bid was refused by Celesio

Celesio shareholder Elliott remains opposed to McKesson’s company acquisition bid.

The costs of creating new drugs revealed

A recent survey by Forbes has revealed the true cost of generating new drugs by looking at number of new product launches compared to R&D spend over the same period

Merck & Co: Partnering activity 2005-2013

Merck & Co announced over 260 partnering / licensing deals since 2005, with 38 deals in 2012 alone

Merck & Co: M&A activity 2005-2013

Merck & Co has announced 11 M&A deals since 2005, with the lead deals being the acquisition of SmartCells, Inpire Pharmaceuticals and in 2009 Schering-Plough

Merck & Co: Company profile

Merck & Co, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Current Agreements Deal analysis Update : March 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in February 2013


Sorry, your search returned no results.


Ligon Discovery Collaborates with Bayer Schering Pharma to Discover Potential First-in-Class Small Molecule Therapeutics

Ligon Discovery has partnered with Bayer Schering Pharma to apply its proprietary Small Molecule Microarray screening platform (SMM) to discover potential first-in-class drug candidates for new disease targets

TauRx Therapeutics enters collaborative R&D agreement with Bayer Schering Pharma

Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology.

Prometheus and Bayer Schering Pharma to apply novel diagnostic platform to oncology therapeutic candidates

Prometheus will receive an upfront payment, research and development support and testing fees, and potential additional payments upon the achievement of certain development milestones.

Bayer Schering Pharma exercises option to develop solid tumor BiTE antibody with Micromet

Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

Opko Health completes acquisition of NK-1 compounds from Schering

Rolapitant, a neurokinin-1 (NK-1) receptor antagonist, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

Compugen and Bayer Schering Pharma to collaborate on antibody target drug

Following an initial six month joint research stage, the agreement provides Bayer with an option for an exclusive worldwide royalty bearing license for development of monoclonal antibodies and other therapeutic agents addressing these novel target molecules.

Opko Health acquires lead NK-1 compounds from Schering-Plough

Phase 1 clinical testing has also been initiated for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products.

Galapagos in expanded drug discovery deal with BioFocus DPI and Schering-Plough Research Institute

BioFocus DPI, has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). Under the terms of the agreement, BioFocus DPI will perform medicinal chemistry with supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects. Total contract value for Galapagos is EUR 2.8 M over a one year period.

Algeta signs global agreement with Bayer Schering Pharma for development and commercialization of Alpharadin for bone metastases

Algeta has an option for up to 50% co-promotion with Bayer in the United States under a profit-share arrangement. Bayer will commercialize Alpharadin globally and pay tiered double-digit royalties on net sales in markets where there is no co-promotion.

Celera grants license to Bayer Schering for cancer-related targets

Bayer Schering Pharma will pay Celera a one-time fee for the exclusive access to the five targets. Additional payments are due upon achievement of certain development and commercial milestones.